Determinants of risk factors of atherosclerosis in the postinfarction period: The Tallinn MI Study

References

• Health Statistics. 2003. Atlas on mortality in the European Union. Chapter 8. Cardiovascular diseases. Office for Official Publications of the European Communities. http://europa.eu.int
   Google Scholar
• Baburin A., Gornoi K., Leinsalu M., Rahu M. Atlas of mortality in Estonia: Institute of Experimental and Clinical Medicine. Report of Grant EST0171 from the Swedish International Development Cooperation Agency. Printall, Estonia 1997, ISBN 9985‐60‐218‐8
   Google Scholar
• Porkka K. V. K., Taimela S., Kontula K., Lehtimäki T., Aalto‐Setälä K., Åkerblom H. K., et al. Variability gene effects of DNA polymorphisms at the apoB, apo A I/C III and apoE loci on serum lipids: the Cardiovascular Risk in Young Finns Study. Clin Genet 1994; 45: 113–21
   PubMed Web of Science ®Google Scholar
• Dammerman M., Breslow J. L. Genetic basis of lipoprotein disorders. Circulation 1995; 91: 505–12
   PubMed Web of Science ®Google Scholar
• Weisgraber K. H., Rall S. C., Mahley R. W. Human E apolipoprotein heterogeneity: cysteine‐arginine interchanges in the amino acid sequence of the the apo E isoforms. J Biol Chem 1981; 256: 9077–83
   PubMed Web of Science ®Google Scholar
• Ehnholm C., Lukka M., Kuusi T., Nikkilä E., Utermann G. Apolipoprotein E polymorphism in a Finnish population: gene frquencies and relation to lipoprotein concentration. J Lipid Res 1986; 27: 227–35
   PubMed Web of Science ®Google Scholar
• Haddy N., De Backer D., Chemaly M. M., Maurice M., Ehnholm C., Evans A., et al. The importance of plasma apolipoprotein E concentration in addition to its common polymorphism on inter‐individual variation in lipid levels: results from Apo Europe. Eur J Hum Genet 2002; 10: 841–50
   PubMed Web of Science ®Google Scholar
• Wilson P. W. F., Schaefer E. J., Larson M. G., Ordovas J. M. Apolipoprotein E alleles and risk of coronary disease. A meta analysis. Arterioscler Thromb Vasc Biol 1996; 16: 1250–5
   PubMed Web of Science ®Google Scholar
• Chapman M J., Huby T., Nigon F., Thillet J. Lipoprotein (a): implication in atherothrombosis [review]. Atherosclerosis 1994; 110(Suppl)S69–75
   PubMed Web of Science ®Google Scholar
• McLean J. W., Tomlison J. E., Kuang W., Eaton D. L., Chen E. Y., Fless G. M., et al. cDNA sequenceof human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 300: 132–7
   Web of Science ®Google Scholar
• Boerwinkle E., Leffert C. C., Lin J., Lacner C., Chiesa G., Hobbs H. H. Apolipoprotein(a) gene accounts for greater than 90 % of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992; 90: 52–60
   PubMed Web of Science ®Google Scholar
• Kostner G. M., Avogaro P., Gazzolato G., Marth E., Bittolo‐Bon G., Quinci G. B. Lipoprotein Lp(a) and the risk of myocardial infarction. Atherosclerosis 1981; 38: 51–61
   PubMed Web of Science ®Google Scholar
• Dahlen G. H. Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis 1994; 108: 111–26
   PubMed Web of Science ®Google Scholar
• Jauhiainen M., Koskinen P., Ehnholm C., Frick M. H., Mänttäri M., Manninen V., et al. Lipoprotein(a) and coronary heart disease risk: a nested case‐control study of the Helsinki Heart Study participants. Atherosclerosis 1991; 89: 59–67
   PubMed Web of Science ®Google Scholar
• Klausen I. C., Beisiegel U., Menzel H. ‐. J., Rosseneu M., Nicaud V., Faergeman O., on behalf of the EARS Group. Apo(a) phenotypes and Lp(a) concentrations in offspring of men with and without myocardial infarction., Arterioscler Thromb Vasc Biol. 15. 1001–8
   Google Scholar
• Grimby G. Physical activity and muscle training in the elderly. Acta Med Scand 1986, Suppl 711: 233–7
   PubMedGoogle Scholar
• Kostner G. M., Avogaro P., Bittolo Bon G., Cazzolato G., Quinci G. B. Determination of high‐density lipoproteins: screening methods compared. Clin Chem 1979; 25: 939–42
   PubMed Web of Science ®Google Scholar
• Friedewald W. T., Levy R. J., Fredricson D. S. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502
   PubMed Web of Science ®Google Scholar
• Havekes L. M., De Knijff P., Beisiegel U., Havinga J., Smit M., Klasen E. A rapid micromethod for apolipoprotein E phenotyping directly in serum. J Lipid Res 1987; 28: 455–63
   PubMed Web of Science ®Google Scholar
• Hixon J. E., Vernier D. T. Restriction isotyping of human apoliporotein E by gene amplification and cleavage with HhaI. J Lipid Res 1990; 31: 545–8
   PubMed Web of Science ®Google Scholar
• Sundvall J., Sulonen G. ‐B., Hiltunen O., Kiuru J., Pursiainen M., Jauhiainen M. Comparison of a new immunoturbidimetric assay of human serum lipoprotein(a) to the ELISA and the IRMA methods. Scand J Clin Lab Invest 1995; 55: 171–80
   PubMed Web of Science ®Google Scholar
• Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haemotol 1957; 17: 237–47
   PubMedGoogle Scholar
• Stata Base Reference Manual (4 volumes). Stata Press; 2003. 1‐881228‐69‐X Vol. 1–4, 1837 pp
   Google Scholar
• MedCalc for Windows. Statistics for Biomedical Research. Frank Schoonjans, Belgium ©1993–1999
   Google Scholar
• Assmann G., Schulte H. European lipid guidelines: therapeutic recommendations. Am J Cardiol 1989; 63: 53H–5H
   PubMed Web of Science ®Google Scholar
• Luc G., Bard J. M., Arveiler D., Evans A., Cambou J. P., Bingham A., et al. Impact of apolipoprotein E polymorphism on lipoproteins and risk of myocardial infarction. The ECTIM Study. Arterioscler Thromb 1994; 14: 1412–9
   PubMed Web of Science ®Google Scholar
• Parra H. J., Arveiler D., Evans A., Cambou J. P., Amouyel P., Bingham A., et al. A case‐control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study. Arterioscler Thromb 1992; 12: 701–7
   PubMed Web of Science ®Google Scholar
• Mediene‐Benchekor S., Brousseau T., Richard F., Benhamamouch S., Amouyel P., the ECTIM Study Group. Blood lipid concentrations and risk of myocardial infarction., Lancet. 358. 1064–5
   Google Scholar
• Walldius G., Junger I., Holme I., Aastveit A. H., Kolar W., Steiner E. High apolipoprotein B, low apolipoprotein A‐I, and improvement in the prediction of fatal myocardial infarction (AMORIS Study): a prospective study. Lancet 2001; 358: 2026–33
   PubMed Web of Science ®Google Scholar
• Rosseneu M., Fruchart J. C., Bard J. M., Nicaud V., Vinaimont N., Cambien F., et al. Plasma apolipoprotein concentrations in young adults with a parental history of premature coronary heart disease and in control subjects. The EARS Study. Circulation 1994; 86: 1967–73
   Web of Science ®Google Scholar
• Hallman D. M., Boerwinkle E., Saha N., Sandholzer C., Menzel H. J., Csázár A., et al. The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in nine populations. Am J Hum Genet 1991; 49: 338–49
   PubMed Web of Science ®Google Scholar
• VanBockxmeer F. M., Mamotte C. D. S. Apolipoprotein ϵ4 homozygosity in young men with coronary heart disease. Lancet 1992; 340: 879–80
   PubMed Web of Science ®Google Scholar
• Liu S., Ma J., Ridker P. M., Breslow J. L., Stampfer M. J. A prospective study of the association between APOE genotype and the risk of myocardial infarction among apparently healthy men. Atherosclerosis 2003; 166: 323–9
   PubMed Web of Science ®Google Scholar
• Scaglione L., Bergerone S., Gambio R., Imazio M., Macchia G., Cravetto A., et al. Role of lipid apolipoprotein levels and apolipoprotein E genotype in young Italian patients with myocardial infarction. Nutr Metab Cardiovasc Dis 1999; 9: 118–24
   PubMed Web of Science ®Google Scholar
• Humphries S. E., Ordovas J. M. Genetics and atherosclerosis: broadening the horizon. Atherosclerosis 2001; 154: 517–9
   PubMed Web of Science ®Google Scholar
• Rantala M., Savolainen J., Kervinen K., Kesäniemi Y. A. Apolipoprotein E phenotype and diet‐induced alteration in blood pressure. Am J Clin Nutr 1997; 65: 543–50
   PubMed Web of Science ®Google Scholar
• Humphries S. E., Talmud P. J., Hawe E., Bolla M., Day I. N. M., Miller G. J. Apolipoprotein E4 and coronary heart disease in middle‐aged men who smoke: a prospective study. Lancet 2001; 358: 115–9
   PubMed Web of Science ®Google Scholar
• Karvonen J., Kauma H., Kervinen K., Ukkola O., Rantala M., Päivänsalo M., et al. Apolipoprotein E polymorphism affects carotid artery atherosclerosis in smoking hypertensive men. J Hypertension 2002; 20: 2371–8
   PubMed Web of Science ®Google Scholar
• Humphries S. E., Ridker P. M., Talmud P. J. Genetic testing for cardiovascular disease susceptibility: a useful clinical management tool or possible misinformation?. Arterioscl Thromb Vasc Biol 2004; 24: 628–36
   PubMed Web of Science ®Google Scholar
• Saarelainen S., Lehtimäki T., Nikkilä M., Solakivi T., Nieminen M. M., Jaakkola O. Association between apolipoprotein E alleles and autoantibodies against oxidised low‐density lioprotein. Clin Chem Lab Med 2000; 38: 477–8
   PubMed Web of Science ®Google Scholar
• Ranallo R. F., Rhodes E. C. Lipid metabolism during exercise [review]. Sports Med 1998; 26: 29–42
   PubMed Web of Science ®Google Scholar
• Berg A., Halle M., Franz I., Keul J. Physical activity and lipoprotein metabolism: epidemiological evidence and clinical trials [review]. Eur J Med Res 1997; 2: 259–64
   PubMedGoogle Scholar
• Kharb S., Singh G. P. Effect of smoking on lipid profile, lipid peroxidation and antioxidant status in normal subjects and in patients during and after acute myocardial infarction. Clin Chim Acta 2000; 302: 213–9
   PubMed Web of Science ®Google Scholar
• Langer R. D., Criqui M. H., Reed D. M. Lipoproteins and blood pressure as biological pathways for effect of moderate alcohol consumption on coronary heart disease. Circulation 1992; 85: 910–5
   PubMed Web of Science ®Google Scholar
• Dreon M. D., Krauss R. M. Alcohol, lipids, and lipoproteins. Alcohol and the cardiovascular system. Research Monograph No. 31. National Institute on Alcohol Abuse and Alcoholism, S Zahkari, M Wassef. Government Printing Office, , Washington 1996; 369–91
   Google Scholar
• Temelkova‐Kurktschiev T., Henkel E., Koehler C., Hanefeld M. Light‐to‐moderate alcohol consumption, risk factor profile and early atherosclerosis: the RIAD Study. Atherosclerosis 2001; 156: 239–40
   PubMed Web of Science ®Google Scholar
• Aasvee K., Kurvinen E., Jordania R., Jauhiainen M., Sundvall J. Lipoprotein parameters in relation to other risk factors of atherosclerosis in adults and newborns: Tallinn Young Family Study. Scand J Clin Lab Invest 2004; 64: 245–54
   PubMed Web of Science ®Google Scholar
• Reinhart W. H. Fibrinogen: marker or mediator of vascular disease? [review]. Vasc Med 2003; 8: 211–6
   PubMed Web of Science ®Google Scholar
• Lowe G. D. O. Recent progress in the epidemiology of haemostatic factors. Atherosclerosis XI, B Jacotot, D Mathé, J. ‐D Fruchart. Elsevier Science, Singapore 1998; 57–62
   Google Scholar
• Maeda S., Abe A., Seishima M., Makino K., Noma A., Kawade M. Transient changes of serum lipoprotein(a) as an acute phase protein. Atherosclerosis 1989; 78: 145–50
   PubMed Web of Science ®Google Scholar
• Foody J. A. M., Milberg J. A., Pearce G. L., Sprecher D. L. Lipoprotein(a) associated with coronary artery disease in older women: age and gender analysis. Atherosclerosis 2000; 153: 445–51
   PubMed Web of Science ®Google Scholar
• Navab M., Berliner J. A., Watson A. D., Hama S. Y., Territo M. C., Lusis A. J., et al. The Yin and Yang of oxidation of the fatty streak. A review based on the 1994 Georg Luman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol 1996; 16: 831–42
   PubMed Web of Science ®Google Scholar